formularies

Summary

Summary: Lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.

Top Publications

  1. ncbi Spillover effects of restrictive drug formularies: a case study of PacifiCare in California
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 11:24-6. 2005
  2. ncbi Identifying widely covered drugs and drug coverage variation among Medicare part D formularies
    Chien Wen Tseng
    Department of Family Medicine and Community Health, John A Burns School of Medicine at University of Hawaii, Honolulu, USA
    JAMA 297:2596-602. 2007
  3. ncbi Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary)
    Neda Tavassoli
    Clinical Pharmacology Department, Centre of Pharmacoepidemiology and Drug Information, Pharmacoepidemiology Unit, Faculty of Medicine, Paul Sabateir University, Toulouse, France
    Drug Saf 30:1063-71. 2007
  4. ncbi Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid
    Matthew M Murawski
    Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmacal Sciences, West Lafayette, IN 47907 2051, USA
    Am J Manag Care 11:SP35-42. 2005
  5. ncbi Effects of restrictive formularies in the ambulatory care setting
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Canada
    Am J Manag Care 8:69-76. 2002
  6. ncbi The effect of incentive-based formularies on prescription-drug utilization and spending
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 349:2224-32. 2003
  7. ncbi Physicians' views of formularies: implications for Medicare drug benefit design
    Bruce E Landon
    Harvard Medical School, Beth Israel Deaconess Medical Center, USA
    Health Aff (Millwood) 23:218-26. 2004
  8. ncbi Incentive formularies and changes in prescription drug spending
    Bruce E Landon
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Am J Manag Care 13:360-9. 2007
  9. pmc The new medicare drug benefit: formularies and their potential effects on access to medications
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, Mass, USA
    J Gen Intern Med 20:662-5. 2005
  10. ncbi Consumer knowledge and perceptions of formularies
    Sujit S Sansgiry
    University of Houston, College of Pharmacy, Houston, Texas 77030, USA
    Manag Care Interface 17:21-6, 30. 2004

Detail Information

Publications226 found, 100 shown here

  1. ncbi Spillover effects of restrictive drug formularies: a case study of PacifiCare in California
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 11:24-6. 2005
    ..A restrictive drug formulary may influence how physicians treat other, unaffiliated patients, a phenomenon known as the "spillover effect." In a previous study we found significant spillover effects from Maine's Medicaid formulary...
  2. ncbi Identifying widely covered drugs and drug coverage variation among Medicare part D formularies
    Chien Wen Tseng
    Department of Family Medicine and Community Health, John A Burns School of Medicine at University of Hawaii, Honolulu, USA
    JAMA 297:2596-602. 2007
    Clinicians can find it difficult to know which drugs are covered for their Medicare patients because formularies vary widely among Medicare Part D plans and many states have 50 or more such plans.
  3. ncbi Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary)
    Neda Tavassoli
    Clinical Pharmacology Department, Centre of Pharmacoepidemiology and Drug Information, Pharmacoepidemiology Unit, Faculty of Medicine, Paul Sabateir University, Toulouse, France
    Drug Saf 30:1063-71. 2007
    ..Cholinesterase inhibitors (ChEIs) could be involved in several drug-drug interactions (DDIs) because of their complex pharmacodynamic and/or pharmacokinetic properties...
  4. ncbi Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid
    Matthew M Murawski
    Department of Pharmacy Practice, Purdue University School of Pharmacy and Pharmacal Sciences, West Lafayette, IN 47907 2051, USA
    Am J Manag Care 11:SP35-42. 2005
    ....
  5. ncbi Effects of restrictive formularies in the ambulatory care setting
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, Canada
    Am J Manag Care 8:69-76. 2002
    To determine the consequences of restrictive formularies in the ambulatory care setting in 4 areas: overall drug expenditures, overall healthcare spending, changes in the quality of prescribing, and health outcomes.
  6. ncbi The effect of incentive-based formularies on prescription-drug utilization and spending
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 349:2224-32. 2003
    Many employers and health plans have adopted incentive-based formularies in an attempt to control prescription-drug costs.
  7. ncbi Physicians' views of formularies: implications for Medicare drug benefit design
    Bruce E Landon
    Harvard Medical School, Beth Israel Deaconess Medical Center, USA
    Health Aff (Millwood) 23:218-26. 2004
    ..Physicians Survey, a large, nationally representative study of physicians, to learn about physicians' views of formularies. Our results suggest that several aspects of formularies are associated with physicians' positive views about ..
  8. ncbi Incentive formularies and changes in prescription drug spending
    Bruce E Landon
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Am J Manag Care 13:360-9. 2007
    To examine the impact of incentive formularies on prescription drug spending shifts in formulary compliance, use of generic medications, and mail-order fulfillment in the year after introduction of a new pharmacy benefit strategy.
  9. pmc The new medicare drug benefit: formularies and their potential effects on access to medications
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, Mass, USA
    J Gen Intern Med 20:662-5. 2005
    ..Relatively little attention was paid to details about how plans would operate, such as the design of drug formularies. Yet, formularies will be important tools for controlling costs, and may be as important as nominal benefit ..
  10. ncbi Consumer knowledge and perceptions of formularies
    Sujit S Sansgiry
    University of Houston, College of Pharmacy, Houston, Texas 77030, USA
    Manag Care Interface 17:21-6, 30. 2004
    A study was undertaken to determine consumer knowledge and perceptions of formularies. A prevalidated survey containing 11 scored items was administered to 714 consumers waiting to receive prescription medications at 72 community ..
  11. ncbi Consumer response to dual incentives under multitiered prescription drug formularies
    Boyd H Gilman
    Mathematica Policy Research, Inc, Cambridge, MA 02139, USA
    Am J Manag Care 13:353-9. 2007
    To decompose the overall effect of multitiered formularies on drug utilization and spending into the following 2 observed effects on consumer behavior: first, higher copayments on drug equivalents create an incentive to reduce the number ..
  12. ncbi Designing pediatric vaccine formularies and pricing pediatric combination vaccines using operations research models and algorithms
    Sheldon H Jacobson
    Department of Mechanical and Industrial Engineering, University of Illinois, Urbana, USA
    Expert Rev Vaccines 2:15-9. 2003
    ....
  13. ncbi Access to drug therapy and substitution between alternative antidepressants following an expansion of the California Medicaid formulary
    Jeffrey S McCombs
    Department of Pharmaceutical Economics and Policy, USC School of Pharmacy, University of Southern California, 1540 E Alcazar St, Rm CHP 140, Los Angeles, CA 90033, USA
    Health Policy 65:301-11. 2003
    ..However, while some expansion in overall antidepressant use may have been desired, the clinical validity of this expansion cannot be determined based on the results presented here...
  14. pmc Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA
    Arch Gen Psychiatry 62:435-41. 2005
    ..Many employers and health plans have adopted 3-tier formularies in an attempt to control costs for these and other drugs.
  15. ncbi How effectively do managed care organizations influence prescribing and dispensing decisions?
    Norman V Carroll
    School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA
    Am J Manag Care 8:1041-54. 2002
    To examine the extent to which managed care organizations (MCOs) use formularies, therapeutic interchange, and prior approval and to determine how effectively these tools influence prescribing and dispensing decisions.
  16. ncbi Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana
    Suchin Virabhak
    Department of Economics, Columbia University, New York, NY, USA
    Am J Manag Care 11:SP14-20. 2005
    ..To determine the extent to which the strictness of the criteria used to control utilization of drugs not on a Medicaid preferred drug list (PDL) changes physician prescribing habits for non-Medicaid patients...
  17. ncbi The effect of access restrictions on the vintage of drugs used by Medicaid enrollees
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Am J Manag Care 11:SP7-13. 2005
    ..To examine the extent to which recent Medicaid drug access restrictions, such as preferred drug lists (PDLs), may affect the vintage (or time since Food and Drug Administration approval) of 6 types of drugs used by Medicaid beneficiaries...
  18. pmc Angiotensin receptor blockers on the formularies of Medicare drug plans
    Walid F Gellad
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 1620 Tremont Street, Boston, MA 02120 1613, USA
    J Gen Intern Med 22:1172-5. 2007
    The presence of angiotensin receptor blockers (ARBs) on the formularies of Medicare Part D prescription drug plans (PDPs) is vitally important to the health of seniors who cannot tolerate angiotensin-converting enzyme (ACE) inhibitors.
  19. ncbi How do incentive-based formularies influence drug selection and spending for hypertension?
    Sachin Kamal-Bahl
    Pharmaceutical Health Services Research Program, School of Pharmacy, University of Maryland Baltimore, USA
    Health Aff (Millwood) 23:227-36. 2004
    This study examined the association between incentive-based formularies and antihypertensive drug selection and spending. We compared the use of drugs from five drug classes by the number of tiers and copayment differentials...
  20. ncbi States' control of prescription drug spending: a heterogeneous approach
    Nancy E Morden
    University of Washington, in Seattle, USA
    Health Aff (Millwood) 24:1032-8. 2005
    ....
  21. ncbi Formularies, therapeutics, and outcomes: new opportunities
    D S Pete Fullerton
    Pharmaceutical Outcomes Research and Policy Program, College of Pharmacy, University of Washington, Seattle, Washington 98105, USA
    Med Care 42:III39-44. 2004
    ..patient compliance and health outcomes after implementation of a Medicare prescription drug benefit, and the need for new types of clinical trials that can respond to changing demands of pharmacy and therapeutics committees and providers..
  22. ncbi Incentives and pharmaceutical reimbursement reforms in Spain
    Jaume Puig-Junoy
    Research Centre for Health and Economics CRES, Department of Economics and Business, Pompeu Fabra University, C Trias Fargas 25 27, 34 08005 Barcelona, Spain
    Health Policy 67:149-65. 2004
    ..In the final section of this paper, we present an overall assessment of the impact of these pharmaceutical reimbursement policies on the behaviour of the agents in the pharmaceutical market...
  23. ncbi Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors
    Y Richard Wang
    Health Services Research and Policy Analysis, Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 5437, USA
    Manag Care Interface 18:39-45. 2005
    ..They found that although drug formulary restrictiveness increases the use of preferred products, it also leads to a high level of formulary noncompliance. The net financial effect on drug spending is ambiguous...
  24. ncbi Evaluating the nondrug costs of formulary coverage restrictions
    Paul Abourjaily
    Tufts New England Medical Center, 750 Washington St Boston, MA 02111, USA
    Manag Care 14:50-7, 62. 2005
    ..To explore the effect of these initiatives, we sought clinicians' feedback regarding their practices and processes for switching patients' medications to accommodate insurance coverage...
  25. ncbi The effect of generic competition on the price of brand-name drugs
    Joel Lexchin
    Emergency Department, University Health Network, Toronto, Ont, Canada
    Health Policy 68:47-54. 2004
    ..Literature from the US has shown that brand-name manufacturers do not compete on price once generic competitors become available. This study was undertaken to investigate if this is also true in Canada...
  26. ncbi Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    Pamela B Landsman
    Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
    Am J Manag Care 11:621-8. 2005
    ..To estimate responsiveness of prescription demand within 9 therapeutic classes to increased cost-sharing compared with constant cost-sharing...
  27. ncbi Prescription drug benefits under Part D of the Medicare Modernization Act--the genie's out of the bottle
    L Sue Andersen
    Health Benefits ABCs
    Issue Brief Cent Medicare Educ 5:1-10. 2005
    ..In this brief, we discuss the new Part D benefit, including who is eligible, the basic benefit, benefits for low-income individuals and coordination with other prescription drug coverage...
  28. ncbi The subsidy of pharmaceuticals in Australia: processes and challenges
    Lloyd Sansom
    School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia
    Aust Health Rev 28:194-205. 2004
    ..The relevant issues are discussed in this article to assist that debate...
  29. ncbi Effects of electronic prescribing on formulary compliance and generic drug utilization in the ambulatory care setting: a retrospective analysis of administrative claims data
    S Michael Ross
    Advanced Concepts Institute, 600 South 43rd Street, Philadelphia, PA 19104, USA
    J Manag Care Pharm 11:410-5. 2005
    ..Electronic prescribing (e-prescribing) provides formulary information at the point of care. The objective of this study was to assess the effects of e-prescribing on formulary compliance and generic utilization...
  30. ncbi Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease
    Kavita V Nair
    University of Colorado Health Sciences Center, School of Pharmacy, 4200 East Ninth Ave, Box C 238, Denver, CO 80262, USA
    J Manag Care Pharm 9:123-33. 2003
    ..To evaluate the impact of 3-tier (copayment) pharmacy benefit structures on medication utilization behavior...
  31. ncbi Budget impact of tegaserod on a managed care organization formulary
    Michael A Bloom
    Innovative Health Solutions, Brookline, Massachusetts, USA
    Am J Manag Care 11:S27-34. 2005
    ..When the associated budget impact of adding tegaserod to its formulary is absorbed across an entire MCO population, the PMPM impact of tegaserod is small...
  32. ncbi Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs
    Becky Briesacher
    Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester 01605, USA
    Arch Intern Med 164:1679-84. 2004
    Previous studies of 3-tier formularies are rare, although the evidence suggests that their cost-sharing structure reduces overall drug spending...
  33. ncbi Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
    Michael A Fischer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02120, USA
    N Engl J Med 351:2187-94. 2004
    ..To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries...
  34. ncbi Medicare Part D: an overview of its practical and clinical impact
    Steve Usdin
    BioCentury Publications, Washington, DC 20009, USA
    Am J Geriatr Cardiol 14:284-8; quiz 289-90. 2005
    ..have to help their patients navigate the new benefit as well as adjust their practices to deal with multiple formularies with different coverage policies...
  35. ncbi Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs
    Kathleen A Fairman
    Express Scripts, Inc, Maryland Heights, Missouri 63043, USA
    Clin Ther 25:3147-61; discussion 3144-6. 2003
    ..Assessment of such systems with a longer follow-up period has been needed...
  36. ncbi Approaches to pharmacy benefit management and the impact of consumer cost sharing
    Bridget M Olson
    The University of Arizona, College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, Tucson, Arizona 85721 0207, USA
    Clin Ther 25:250-72. 2003
    ..An understanding of the most prominent mechanisms of benefit management is an important step in determining the most effective approach to take in future years...
  37. ncbi Do consumers' attitudes predict prescription purchasing behavior?
    Kavita V Nair
    School of Pharmacy, University of Colorado Health Sciences Center, Denver, USA
    Manag Care Interface 16:22-7, 55. 2003
    ..The findings appear to support the concept of three-tier plans, and increasing copayments seems to facilitate greater adherence to health plan formularies.
  38. ncbi Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making
    C Daniel Mullins
    School of Pharmacy, Center on Drugs and Public Policy, University of Maryland, Baltimore, Maryland, USA
    Pharmacoeconomics 20:9-21. 2002
    ..Direct comparator studies are starting to emerge, but in limited numbers. The need for additional training of pharmaceutical representatives and PBM staff members remains a critical issue...
  39. ncbi Comparing patient access to pharmaceuticals in the UK and US
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Appl Health Econ Health Policy 5:177-87. 2006
    ..Additional barriers have since been identified. These pertain to reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles...
  40. ncbi Overview of Medicare Part D prescription drug benefit: potential implications for patients with psychotic disorders
    Jack M Rosenberg
    International Drug Information Center, Brooklyn, NY 11201, USA
    Am J Health Syst Pharm 64:S18-23; quiz S24-5. 2007
    ..Medicare Part D prescription drug benefits are reviewed. Potential implications for patients with psychotic disorders in relation to Medicare Part D are discussed...
  41. ncbi Per-patient-per-month drug costs in Medicare Part D protected classes
    Lisa Mucha
    Thomson Medstat, Cambridge, MA 02140, USA
    Pharmacoeconomics 24:79-84. 2006
    ....
  42. ncbi Patient access to pharmaceuticals: an international comparison
    Joshua Cohen
    Tufts Center for the Study of Drug Development, Boston, MA 02111, USA
    Eur J Health Econ 8:253-66. 2007
    ..At the same time, our study confirms, qualitatively, different kinds of access problems in the US: relatively high patient cost sharing for pharmaceuticals, and wide variation in coverage...
  43. ncbi Management of access to branded psychotropic medications in private health plans
    Dominic Hodgkin
    Institute for Behavioral Health, Schneider Institutes, Heller School of Social Policy and Management, Brandeis University, Waltham, Massachusetts 02454 9110, USA
    Clin Ther 29:371-80. 2007
    ..health insurers have increased their reliance on cost control policies such as prior authorization and 3-tier formularies. Little is known about how these policies are being applied to psychotropic medications, many of which have low ..
  44. pmc Availability of addiction medications in private health plans
    Constance M Horgan
    Institute for Behavioral Health, Schneider Institutes for Health Policy, Heller School for Social Policy and Management, Brandeis University, Waltham, MA 02454, USA
    J Subst Abuse Treat 34:147-56. 2008
    ..Thirty-one percent of insurance products excluded buprenorphine from formularies, whereas 55% placed it on the highest cost-sharing tier...
  45. ncbi Physician dispensing: an old idea is new again
    J Scott Nystrom
    Great Lakes Cancer Management Specialists, Grosse Pointe Woods, MI, USA
    MGMA Connex 6:36-41, 1. 2006
    ..With physician-dispensing prescription costs 50 percent below the national average and generic substitution 50 percent higher than the national average, the potential cost savings for payers and consumers is staggering...
  46. ncbi Shifting the focus from cost to value: a government perspective
    Babette S Edgar
    Gorman Health Group, LLC, 2176 Wisconsin Ave, NW, Washington, DC 20007, USA
    J Manag Care Pharm 12:S11-5; quiz S24-6. 2006
    ..To examine the federal government.s current health care initiatives in the Centers for Medicare and Medicaid Services (CMS) to improve quality of care and cost-effectiveness around the prescription drug benefit...
  47. pmc Prior authorization of newer insomnia medications in managed care: is it cost saving?
    Rajesh Balkrishnan
    College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    J Clin Sleep Med 3:393-8. 2007
    ....
  48. ncbi Perverse incentives in the Medicare prescription drug benefit
    David McAdams
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Inquiry 44:157-66. 2007
    ..In particular, if all plans were required to charge the same premium, there would be less diversity in quality, but also less need to regulate formulary composition, less budgetary uncertainty, and less upward pressure on drug prices...
  49. ncbi Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions
    Sanjoy Roy
    Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, WV 26505, USA
    Pharmacoeconomics 26:281-96. 2008
    ....
  50. ncbi Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006
    Jennifer Bowman
    Avalere Health LLC in Washington, DC, USA
    Health Aff (Millwood) 25:1240-8. 2006
    ..Individual Part D plans have discretion to determine their formularies and cost sharing for drugs within federal guidelines...
  51. ncbi Ethical principles for psychiatric administrators: the challenge of formularies
    H Steven Moffic
    Psychiatry and Family and Community Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    Psychiatr Q 77:319-27. 2006
    ..One such product could be medication algorithms that also incorporate costs, side effects, and general healthcare...
  52. ncbi Reframing the pharmaceutical manufacturer/health plan relationship in managed care
    Ira Studin
    Stellar Managed Care, Cherry Hill, NJ 08003, USA
    Manag Care 11:46, 49-54. 2002
    ....
  53. ncbi Clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company to assure appropriate care under Medicare Part D
    Richard S Blum
    St Francis Hospital, Roslyn, NY, USA
    J Clin Pharmacol 46:394-7. 2006
    ..Drug formularies, including those available to enrollees in Medicare Part D, are based on group characteristics and financial ..
  54. ncbi The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass, USA
    Arch Intern Med 166:332-7. 2006
    ..We studied whether patients enrolled in such plans who receive generic or preferred brand-name agents when initiating chronic therapy were more adherent to treatment than those who received nonpreferred brand-name medications...
  55. ncbi Do drug formulary policies reflect evidence of value?
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 12:30-6. 2006
    To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs).
  56. ncbi Implications of Part D for mentally ill dual eligibles: a challenge for Medicare
    Nancy E Morden
    Department of Family Medicine, University of Washington School of Medicine, Seattle, USA
    Health Aff (Millwood) 25:491-500. 2006
    ..We discuss the details and policy implications of this challenge...
  57. ncbi United States pharmacopeia development of the Medicare model formulary guidelines
    Leonard Bielory
    University of Medicine and Dentistry of New Jersey UMDNJ New Jersey Medical School, Newark, NJ 07081, USA
    Am J Geriatr Cardiol 14:301-7. 2005
    Prescription drug formularies are a key element in prescription drug benefit management. The use of formularies can both increase the quality of prescribing and reduce the costs of prescription drug therapy...
  58. ncbi A first look at the new Medicare prescription drug plans
    Austin B Frakt
    Veterans Affairs Boston Healthcare System in Boston, Massachusetts, USA
    Health Aff (Millwood) 25:W252-61. 2006
    ..One national stand-alone drug plan, though, covers brand-name drugs with no gap. Variations in cost sharing and formularies provide beneficiaries with choices as well as complexity.
  59. ncbi The economic burden associated with prior authorizations in an allergist office
    Don A Bukstein
    Department of Allergy, Dean Medical Center, Madison, Wisconsin 53715, USA
    Allergy Asthma Proc 27:119-22. 2006
    ..Specialty physicians should have a different process for obtaining notformulary medications because almost 100% of their requests are granted...
  60. ncbi Prediction of Medicare drug formulary drugs for treatment of overactive bladder
    Joseph A Grocela
    Department of Urology, Massachusetts General Hospital, Bigelow 1102, Boston, MA 02114, USA
    J Urol 176:252-5; discussion 255-6. 2006
    ..Establishment of the Medicare Part D drug formulary will allow cost containment but still absorb patient and physician preferences as well as a consideration of efficacy and safety data...
  61. ncbi Preparing residents for managed care practice using an experience-based curriculum
    A G Gomez
    UCLA School of Medicine, Sepulveda Veterans Health Administration Medical Center, CA 91343, USA
    Acad Med 72:959-65. 1997
    ..where they will be expected to arrive skilled in managed care activities such as prescribing with formularies and adhering to preauthorization processes for procedures, referrals, and hospital admissions...
  62. ncbi Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia
    Frank J Molnar
    Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    J Am Geriatr Soc 57:536-46. 2009
    ..detect clinically important difference) and for decisions regarding whether medications should be accepted on formularies and should be funded...
  63. ncbi Utilization of restricted antibiotics in a university hospital in Thailand
    Sasima Kusuma Na Ayuthya
    Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 34:179-86. 2003
    ..used to control antibiotic usage including the use of an antibiotic order form (AOF), restricted antibiotic formularies and provision of educational information...
  64. ncbi Teaching the basics of clinical pharmaceutical care: innovative pharmacy workshops at the University of Wisconsin and the University of Nebraska
    Dean R Keller
    Department of Internal Medicine, University of Wisconsin, WI 53706, USA
    Fam Med 36:S89-92. 2004
    Safe and effective prescription writing, using drug formularies, and managing pharmaceutical care are skills medical students need to acquire...
  65. ncbi Use of antipsychotic medications in treating schizophrenia among different financing and delivery systems
    Joan R Bloom
    School of Public Health, Uuniversity of California, Berkeley, CA 94720 7360, USA
    J Ment Health Policy Econ 6:163-71. 2003
    ..Pharmaceuticals were not included in the capitation rate. However, antipsychotic medications were included in the formularies for consumers who received their medical care through a Health Maintenance Organization (HMO).
  66. ncbi Prescribing and dispensing activities at the health facilities of a non-governmental organization
    A Hazra
    Community Development Medicinal, Unit Documentation Centre, Calcutta, West Bengal, India
    Natl Med J India 13:177-82. 2000
    ..Prescribing and dispensing surveys are pre-requisites to achieving rational drug use. There is a dearth of such studies in India, particularly in the non-governmental organization sector...
  67. ncbi Hospital policies for treatment of acute decompensated heart failure
    Vikrant Vats
    Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
    Ann Pharmacother 41:562-7. 2007
    ..It is unclear to what extent hospitals use guidelines or protocols in treating acute decompensated heart failure (ADHF) and whether nesiritide is included in these guidelines or protocols...
  68. pmc Information resource preferences by general pediatricians in office settings: a qualitative study
    George R Kim
    Division of Health Sciences Informatics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    BMC Med Inform Decis Mak 5:34. 2005
    ..Information needs and resource preferences of office-based general pediatricians have not been well characterized...
  69. ncbi Toward a standard drug formulary for the treatment of headache
    J A Klapper
    Colorado Neurology and Headache Center, Denver, USA
    Headache 35:225-7. 1995
    The recent publication of drug formularies by third-party payers has serious implications for the practice of medicine. These formularies list the medications for which the consumer can be reimbursed by the third-party payer...
  70. ncbi Implementing the new guidelines for hypertension: JNC 7, ADA, WHO-ISH
    Barry L Carter
    Division of Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, 511 South Grand, Iowa City, IA 52240, USA
    J Manag Care Pharm 10:S18-25. 2004
    ..The strategies for lowering BP levels include patient lifestyle changes, adherence to therapy, and regular monitoring of BP levels...
  71. ncbi Are incentive-based formularies inversely associated with drug utilization in managed care?
    Patrick P Gleason
    Prime Therapeutics, LLC, Eagan, MN 55121 3497, USA
    Ann Pharmacother 39:339-45. 2005
    To review recent studies comprehensively assessing the impact of incentive-based multitier formularies on pharmaceutical costs and utilization.
  72. ncbi [Prescribing and dispensing generic drugs in the Mambéré-Kadéï health district of the Central African Republic]
    C Mouala
    Faculté des Sciences de la Santé BP 1383 Bangui, RCA
    Med Trop (Mars) 68:149-54. 2008
    ..dispensed drugs, and lack of access to standard drug use tools such as a locally adapted essential drug list, formularies and standard treatment guidelines...
  73. ncbi Clinical outcome of a mandatory formulary switch for dihydropyridine calcium channel blocker therapy at a Veteran's Administration Medical Center
    G Gustin
    Section of Hypertension and Vascular Diseases, University of Connecticut School of Medicine, Farmington, USA
    Am J Hypertens 9:312-6. 1996
    ..antihypertensive therapies with similar properties have been made based primarily on cost savings for hospital formularies. To assess blood pressure (BP) control and adverse side effects associated with a switch of patients on ..
  74. ncbi Teaching of medical informatics in UME-21 medical schools: best practices and useful resources
    Craig L Gjerde
    Department of Family Medicine, University of Wisconsin 53706, USA
    Fam Med 36:S68-73. 2004
    ....
  75. ncbi Engineering the economic value of two pediatric combination vaccines
    Sheldon H Jacobson
    Department of Mechanical and Industrial Engineering, University of Illinois, Urbana, IL 61801, USA
    Health Care Manag Sci 8:29-40. 2005
    ..of the paper is to provide a methodology for analyzing the impact of combination vaccines on pediatric vaccine formularies. This analysis shows that the DTPa-HBV-IPV vaccine may provide a good value at the current federally negotiated ..
  76. ncbi Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugs
    William H Shrank
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02120 1613, USA
    Ann Pharmacother 40:1534-40. 2006
    Most insurers in the US have implemented incentive-based formularies that rely on out-of-pocket costs to influence prescription drug utilization. Medicare Part D plans have broadly adopted such benefit designs.
  77. ncbi Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study
    Li Chia Chen
    School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, 1st Floor, Stopford Building, Oxford Road, Manchester, M13 9PT, UK
    Pharm World Sci 29:661-70. 2007
    ....
  78. ncbi Medicine reimbursement recommendations in Canada, Australia, and Scotland
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ontario, Canada M3J 1P3
    Am J Manag Care 14:581-8. 2008
    ..was undertaken to compare the recommendations made by the Canadian Common Drug Review (CDR) regarding whether drugs should be listed on provincial and federal formularies with recommendations made by similar bodies in other countries.
  79. ncbi Infection control programs at children's hospitals: a description of structures and processes
    S Girouard
    National Association of Children s Hospitals and Related Institutions, Alexandria, VA 22314, USA
    Am J Infect Control 29:145-51. 2001
    ..Components of antimicrobial restriction programs included infectious disease specialist approval, restricted formularies, selective susceptibility test reporting, and staff education programs...
  80. ncbi ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing--2004
    Craig A Pedersen
    Division of Pharmacy Practice and Administration, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210 1291, USA
    Am J Health Syst Pharm 62:378-90. 2005
    ..Results of the 2004 ASHP national survey of pharmacy practice in hospital settings that pertain to prescribing and transcribing are presented...
  81. ncbi The impact of hurricanes and flooding disasters on hymenopterid-inflicted injuries
    James H Diaz
    Environmental and Occupational Health Sciences, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA
    Am J Disaster Med 2:257-69. 2007
    ..to alert regional healthcare providers of the increased risks of hymenopterid-inflicted injuries following flooding disasters and to assure that emergency drug formularies are properly stocked to treat hymenopterid-inflicted injuries.
  82. ncbi Chronic kidney disease and medicare
    Wendy L St Peter
    College of Pharmacy at the University of Minnesota, Minneapolis, MN 55404, USA
    J Manag Care Pharm 13:S13-8. 2007
    ..The ESRD population faces significant hurdles when using the new Part D benefit. To understand those challenges, a basic understanding of Part D is needed...
  83. ncbi Cost comparison of beta 2-agonist bronchodilators used in the treatment of asthma
    C H Nightingale
    School of Pharmacy, University of Connecticut, Storrs, USA
    Pharmacotherapy 15:677-81. 1995
    ..In addition, agents that can be dosed as needed (i.e., albuterol) are likely to be more cost-effective choices for formularies than more expensive new bronchodilators such as salmeterol, which must be given twice/day on a regular basis.
  84. pmc A manifesto for clinical pharmacology from principles to practice
    Jeffrey K Aronson
    University Department of Primary Health Care, Rosemary Rue Building, Old Road Campus, Headington, Oxford OX3 7LF, UK
    Br J Clin Pharmacol 70:3-13. 2010
    ..and general practice; policy makers, framing local, national, and international medicines policy, including formularies, licensing of medicines and prescribing policies. 5...
  85. ncbi Impact of hospital formularies on fluoroquinolone prescribing in emergency departments
    Sherrie L Aspinall
    Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, and Unviersity of Pittsburgh School of Pharmacy, Pittsburgh, PA 15240, USA
    Am J Manag Care 13:241-8. 2007
    ..To examine factors associated with fluoroquinolone prescribing among adults receiving antibiotics for acute respiratory tract infections (ARIs) in emergency departments...
  86. ncbi Pharmaceutical cost containment and innovation in the United States
    N M Kane
    Harvard School of Public Health, Boston, MA 02215, USA
    Health Policy 41:S71-89. 1997
    ..There are no price controls, no national drug formularies, no universal cost-sharing policies, and perhaps most important, no national coverage of prescription drugs...
  87. ncbi Doctorline: a private toll-free telephone medical information service. Five years of activity: old problems and new perspectives
    A Nobili
    Laboratorio di Neuropsichiatria Geriatrica, Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy
    Ann Pharmacother 32:120-5. 1998
    ..In some cases it can be difficult to gain access to the different sources of medical information. In an attempt to overcome these problems, a toll-free telephone medical information service (Doctorline) was established...
  88. ncbi Survey of hospitals for guidelines, policies, and protocols for anticoagulants
    Vikrant Vats
    Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
    Am J Health Syst Pharm 64:1203-8. 2007
    ....
  89. ncbi 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina
    Sohini Sengupta
    Department of Social Medicine, University of North Carolina at Chapel Hill, MacNider Hall, CB 7240, Chapel Hill, NC 27599 7240, USA
    N C Med J 69:6-13. 2008
    ..This analysis examines Medicare Part D antiretroviral coverage in 2007 for beneficiaries with HIV/AIDS in North Carolina, particularly those who did not qualify as dual eligibles or for a full low-income subsidy...
  90. ncbi An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system
    Athena Zuppa
    Clinical Pharmacology and Therapeutics, Abramson Research Center, Suite 916 J, The Children s Hospital of Philadelphia, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA
    J Clin Pharmacol 47:1172-80. 2007
    ..can provide a mechanism to assess drug prescribing trends, efficiency, and cost-effectiveness of hospital formularies and examine subpopulations for which prescribing habits may be different...
  91. ncbi Deaths resulting from hypocalcemia after administration of edetate disodium: 2003-2005
    Mary Jean Brown
    Lead Poisoning Prevention Branch, Division of Emergency and Environmental Health Services, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    Pediatrics 118:e534-6. 2006
    ..providers who are unfamiliar with chelation consult an expert before undertaking treatment and that hospital formularies evaluate whether stocking edetate disodium is necessary, given the risk for hypocalcemia and the availability ..
  92. ncbi Health information technology and physicians' knowledge of drug costs
    Chien Wen Tseng
    Department of Family Medicine and Community Health, University of Hawaii, Honolulu, 96789, USA
    Am J Manag Care 16:e105-10. 2010
    ..To examine whether physicians' use of information technology (IT) was associated with better knowledge of drug costs...
  93. ncbi Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget
    Gregory S Zaric
    Richard Ivey School of Business, University of Western Ontario, Canada
    Health Econ 14:793-803. 2005
    Many public and private healthcare payers use formularies as a tool for controlling drug costs and quality...
  94. ncbi Pharmacists' perceptions of the effectiveness of antimicrobial control programs
    Gail S Itokazu
    College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA
    Am J Health Syst Pharm 63:2504-8. 2006
    ..The perceptions of the effectiveness of antimicrobial control programs (ACPs) among infectious diseases (ID) pharmacists were studied...
  95. ncbi Misleading score-lines on tablets: facilitated intake or fractional dosing?
    Isabelle Arnet
    Pharmaceutical Care Research Group, Pharmazentrum, Basel, Switzerland
    Swiss Med Wkly 140:105-10. 2010
    ..information is expected to be in the Summary of Product Characteristics (SPCs), the package leaflets (PLs) or Hospital Drug Formularies. We investigated the accuracy of splitting statements in these three sources of drug information.
  96. pmc A web-based tool for designing vaccine formularies for childhood immunization in the United States
    Sheldon H Jacobson
    Department of Computer Science, Simulation and Optimization Laboratory, University of Illinois, Urbana, IL 61801, USA
    J Am Med Inform Assoc 15:611-9. 2008
    ..A description of the tool's capabilities is provided. RESULTS on the use of the software tool are reported and discussed...
  97. pmc Implications of CATIE for mental health services researchers
    Nancy H Covell
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    Psychiatr Serv 59:526-9. 2008
    ..Given the complexity and variability of response to antipsychotic medications in CATIE, use of restricted formularies is not the answer...
  98. ncbi Insulin for the world's poorest countries
    J S Yudkin
    Royal Free and University College London School of Medicine, Whittington Hospital, UK
    Lancet 355:919-21. 2000
    ..developing world where insulin availability is intermittent, and insulin may not even be included on national formularies of essential drugs...
  99. ncbi Status and future of vaccines for adults
    J D Grabenstein
    U S Army Medical Department, School of Pharmacy, University of North Carolina, Chapel Hill 27599 7360, USA
    Am J Health Syst Pharm 54:379-87. 1997
    ..Health systems should select tetanus-diphtheria toxoids adsorbed for their formularies for immunizing adults, not monovalent tetanus toxoid...
  100. ncbi Diabetes in Canada: direct medical costs of major macrovascular complications
    J A O'Brien
    Caro Research, 336 Baker Avenue, Concord, MA 01742, USA
    Value Health 4:258-65. 2001
    ..To estimate direct medical costs of managing major macrovascular complications in diabetic patients...
  101. ncbi The formulary process from a risk management perspective
    Jack H Raber
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California School of Pharmacy, Los Angeles, USA
    Pharmacotherapy 30:42S-47S. 2010
    During their evolution over the past 6 decades, hospital formularies have become more than a list of drugs that an institution keeps in stock...

Research Grants47

  1. Tools for Optimizing Prescribing, Monitoring and Education
    Bruce L Lambert; Fiscal Year: 2010
    ..redesign, refine, integrate, test, deploy and disseminate tools and training materials in five key areas: drug formularies, drug utilization review, lab-pharmacy linkages, N-of-1 trials and pharmacoeconomics...
  2. Reducing Cost-Related Medication Nonadherence in Persons with Diabetes
    Chien Wen Tseng; Fiscal Year: 2011
    ..The PG summarizes multiple formularies in a standard format, highlights widely covered drugs, gives retail prices from discount pharmacies, and has ..
  3. Epidemiologic Evaluation of State AIDS Drug Assistance Program Features in the US
    David B Hanna; Fiscal Year: 2012
    ..state to state based on financial eligibility criteria, cost-containment measures, and inclusiveness of drug formularies with respect to antiviral therapies, opportunistic infection prophylaxis, and addiction treatment...
  4. Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs
    Benjamin P Linas; Fiscal Year: 2011
    ..Assistance Program resource prioritization strategies including altering eligibility rules, restructuring drug formularies, and Improving cost projections. 3...
  5. Differences In Incentives Between Stand Alone Medicare Drug Coverage vs Medicare
    Kosali Ilayperuma Simon; Fiscal Year: 2010
    ..After open enrollment, MAPDPs have stronger incentives to design formularies that optimize medical management by generously covering drugs whose use reduces hospital costs (Chandra, Gruber ..
  6. Exploring Therapeutic Resources in Colonial N. America
    Renate Wilson; Fiscal Year: 2003
    The goal of this project is to provide wide and direct access to two rare dispensatories and formularies that illuminate the therapeutic practices and medical orientation of two physicians active in Pennsylvania during the period 1740-..
  7. Intelligent and Practical Geriatric Prescribing Systems
    PAUL GERTMAN; Fiscal Year: 2006
    ..GerRx will use a sophisticated, proven CDS system which references accepted medication guidelines and formularies and leverages relevant patient data for better prescribing...
  8. Effects of Drug Advertising on Prescription Choice
    Marta Wosinska; Fiscal Year: 2001
    ..prescription decision-making, with special attention to the influences of direct-to-consumer advertising, formularies, and cost-sharing requirements...
  9. EVALUATION OF A THREE TIER COPAY
    Brenda Motheral; Fiscal Year: 1999
    ..Tradition tools have included closed formularies and differential copayments for generic and brand products...
  10. 'Fair?' A Study of physicians' responses to restricted *
    Paul Adler; Fiscal Year: 2002
    DESCRIPTION: (Provided by the Applicant) Prior research suggests that restricted formularies--i.e...
  11. Distributed, Collaborative Intelligent Agents for Proactive Post-Marketing Drug S
    Hao Ying; Fiscal Year: 2009
    ..systems and insurers nationwide regularly make decisions regarding which drugs to include or exclude from their formularies based on evidence concerning benefits, risks, and costs of the medications...
  12. The Effects of Formularies and Pharmaceutical Promotion on Physicians' Prescribin
    GREGORY KRUSE; Fiscal Year: 2008
    ..The primary objective is to test the impact of the following factors on drug selection: incentive-based tiered formularies, patient insurance type, pharmaceutical detailing, and pharmaceutical direct-to-consumer advertising...
  13. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2011
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  14. Economics of Formulary Design and Mental Health Policy
    Haiden Huskamp; Fiscal Year: 2006
    ..The second project assesses the economic incentives created by three-tier drug formularies and how these arrangements affect costs, utilization patterns, and adherence to treatment guidelines in a non-..
  15. Clinical Implications of Variation Among Medicare Formularies
    Chien Wen Tseng; Fiscal Year: 2008
    ..However, policymakers[unreadable] are concerned that variation among the formularies of the thousands of drug plans (n = 2,743) offered in[unreadable] Medicare will make it impossible for ..
  16. The Eighteenth Annual Health Economics Conference
    JONATHAN KETCHAM; Fiscal Year: 2007
    ..This year's conference will be held March 16-17 on the campus of Arizona State University in Tempe, AZ. [unreadable] [unreadable] [unreadable]..
  17. The Role of Customization in Psychotropic Prescribing
    Dominic Hodgkin; Fiscal Year: 2009
    ..However, other factors such as formularies may work against customization...
  18. Hospital-Physician Gainsharing
    JONATHAN DAVID KETCHAM; Fiscal Year: 2010
    ..The results can provide timely insights to regulators, policymakers, and managers as they consider various incentive programs to promote value through coordination. ..
  19. Specialty Mental Health Care--Expanding Access in an HMO
    Dominic Hodgkin; Fiscal Year: 2003
    ..The results will inform health plan decision-makers and others as they make utilization management choices that may have a major impact on patients and enrollee populations overall. ..
  20. Impact of 3 Tier Drug Copays on Use and Spending
    Dominic Hodgkin; Fiscal Year: 2003
    ..abstract_text> ..
  21. Financial Incentives and Variations in the Care of Medicare Beneficiaries
    Bruce E Landon; Fiscal Year: 2010
    ..Because patients will be clustered within physicians and physicians clustered within markets, we will use hierarchical analytic methods. ..
  22. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  23. Can Longitudinal Population-Based Data Help to Personalize Depression Treatment?
    Gregory E Simon; Fiscal Year: 2010
    ..We propose a set of targeted methodologic studies to prepare for a multi-site research consortium focused on predicting response to specific depression treatments. ..
  24. Modeling Adherence to Psychotherapy for Depression
    Gregory Simon; Fiscal Year: 2009
    ..The proposed research is one component of an ongoing comprehensive program to understand and increase consumer demand for effective depression treatment. ..
  25. Research Center on Managed Care and Drug Abuse Treatment
    Constance Horgan; Fiscal Year: 2008
    ..This pilot will explore the feasibility for a large-scale study of the incremental impact of adding a substance abuse treatment parity benefit to private health insurance in California. ..
  26. ESCAPE Mechanistic Substudies
    Robert Califf; Fiscal Year: 2003
    ..Catecholamines are also being collected at baseline and 3 months. In addition, the ESCAPE investigators are all ready capturing detailed demographic, clinical, and physiological information as part of the protocol for the primary study. ..
  27. Comparative Safety and Effectiveness of Stimulants in Medicaid Youth with ADHD
    Almut G Winterstein; Fiscal Year: 2010
    ....
  28. DRUG ABUSE TREATMENT UNDER MANAGED CARE--ROLE OF PPOS
    Constance Horgan; Fiscal Year: 2002
    ..This study will provide systematic information on the nature and extent of these changes. ..
  29. Prevalence and Correlates of Psychiatric Disorders among Older Adults
    Scott Novak; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  30. Vulnerable Populations and Special Protections in ACTUs
    Sohini Sengupta; Fiscal Year: 2007
    ..abstract_text> ..
  31. COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER
    Scott Ramsey; Fiscal Year: 2002
    ....
  32. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2003
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
  33. Comparison of Methadone Units Within and Outside the CTN
    LORI DUCHARME; Fiscal Year: 2006
    ..The data to be collected in this study will allow for conclusions about potential barriers to effective dissemination of evidence-based treatment for opiate dependence from CTN units to methadone programs in the "real world." ..
  34. Changing from Conventional to Risperidone Decanoate
    Nancy Covell; Fiscal Year: 2005
    ..Subjects will be interviewed with quantitative instruments at baseline and at follow-up intervals for 1 year. ..
  35. A Genetic Screening Policy Model for Colorectal Cancer
    Scott Ramsey; Fiscal Year: 2006
    ..The model will incorporate QOL information from Aim 2, along with family history, clinical, and screening information from the Seattle CFR. ..
  36. Epidemiology and Care of Comorbid Obesity and Depression
    Gregory Simon; Fiscal Year: 2006
    ..weight loss, nutrient intake, physical activity, depressive symptoms, functional impairment and disability in the two groups of women with comorbid obesity and depression randomly assigned to the two different intervention programs ..
  37. Industry-Sponsored Research Contracts:An Empirical Study
    Michelle Mello; Fiscal Year: 2002
    ..The data will be analyzed descriptively and with chi-squared tests and regression analysis. ..
  38. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2008
    ..To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests [unreadable] [unreadable] [unreadable]..
  39. Pilot Trial of Peer Support for Bipolar Disorder
    Gregory Simon; Fiscal Year: 2006
    ..abstract_text> ..
  40. MD Group Characteristics and Quality of Care for CHD
    Bruce Landon; Fiscal Year: 2003
    ..abstract_text> ..
  41. Industry-Sponsored Research Contracts:..Phase II
    Michelle Mello; Fiscal Year: 2004
    ..abstract_text> ..
  42. Effect of a Restrictive Formulary on Low Income Children
    JULIE URMIE; Fiscal Year: 2007
    ..Instrumental variable analysis will be used to examine the effect of changes in antidepressant prescribing patterns caused by the restrictive formulary on health care costs. [unreadable] [unreadable] [unreadable] [unreadable]..
  43. POPULATION-BASED MANAGEMENT OF DEPRESSION
    Gregory Simon; Fiscal Year: 2003
    ..e. 12-18 mos) Incremental cost and cost-effectiveness of each intervention program compared to care as usual. ..
  44. Reimbursement Policy and Cancer Chemotherapy
    Joseph Newhouse; Fiscal Year: 2009
    ..Understanding its impact on chemotherapy treatment patterns has important implications not only for Medicare spending but also for the welfare of beneficiaries with cancer. ..